During oral evidence to the Infected Blood Inquiry Dr Walford was questioned in relation to concentrates and the UKHDO's stance on the risk they carried. In response to the level of risk she stated that "the risk as they [UKHCDO] were defining it was what they perceived as the risk at the present time". Read more about During oral evidence to the Infected Blood Inquiry Dr Walford was questioned in relation to concentrates and the UKHDO's stance on the risk they carried. In response to the level of risk she stated that "the risk as they [UKHCDO] were defining it was what they perceived as the risk at the present time".
During oral evidence to the Infected Blood Inquiry, Dr Diana Walford stated that it was "a fairly unusual format" to have conclusions already made within an agenda for a committee meeting. This was in reference to an agenda for the Committee on Safety of Medicines Sub-Committee on Biological Products on 13 July 1983. Read more about During oral evidence to the Infected Blood Inquiry, Dr Diana Walford stated that it was "a fairly unusual format" to have conclusions already made within an agenda for a committee meeting. This was in reference to an agenda for the Committee on Safety of Medicines Sub-Committee on Biological Products on 13 July 1983.
Dr Smith wrote to Dr Fowler, stating that it would be advisable to consider the problem of AIDS and blood products at the next meeting of the CSM(B) and asking Dr Fowler to produce a brief paper for the meeting. Read more about Dr Smith wrote to Dr Fowler, stating that it would be advisable to consider the problem of AIDS and blood products at the next meeting of the CSM(B) and asking Dr Fowler to produce a brief paper for the meeting.
The FDA issued a directive to all US manufacturers of plasma derivatives aimed at decreasing the risk of transmitting AIDS, stating that plasma collected from donors in certain high risk groups "should not be fractionated into derivatives already known to have a risk of transmitting infection diseases". Read more about The FDA issued a directive to all US manufacturers of plasma derivatives aimed at decreasing the risk of transmitting AIDS, stating that plasma collected from donors in certain high risk groups "should not be fractionated into derivatives already known to have a risk of transmitting infection diseases".
In a memo Ed Cutter wrote that Cutter might consider being open about the risk of AIDs for those who consumed its products. Read more about In a memo Ed Cutter wrote that Cutter might consider being open about the risk of AIDs for those who consumed its products.
CDC representatives met with leaders from the blood industry (including the Pharmaceutical Manufacturers Association), haemophilia groups, gay community organisations and representatives from the NIH [National Institute of Health] and FDA in Washington. The disease was renamed AIDS and it was agreed that it was caused by an infectious agent. Read more about CDC representatives met with leaders from the blood industry (including the Pharmaceutical Manufacturers Association), haemophilia groups, gay community organisations and representatives from the NIH [National Institute of Health] and FDA in Washington. The disease was renamed AIDS and it was agreed that it was caused by an infectious agent.
An article in MMWR states that it seems likely that the pool of persons capable of transmitting an AIDS agent may be considerably larger than the presently known number of AIDS cases. Also that there may be a latency period of between several months to two years between infection and recognisable clinical illness and that transmissibility may precede illness. Read more about An article in MMWR states that it seems likely that the pool of persons capable of transmitting an AIDS agent may be considerably larger than the presently known number of AIDS cases. Also that there may be a latency period of between several months to two years between infection and recognisable clinical illness and that transmissibility may precede illness.
The CDC reported that blood products or blood appeared responsible for AIDS among haemophilia patients requiring clotting factor replacement. It also noted that the first signs of AIDS might take two to three years to emerge after exposure to a possible transmissible agent. There was a fatality rate of more than 60 percent for those first diagnosed over one year previously. Read more about The CDC reported that blood products or blood appeared responsible for AIDS among haemophilia patients requiring clotting factor replacement. It also noted that the first signs of AIDS might take two to three years to emerge after exposure to a possible transmissible agent. There was a fatality rate of more than 60 percent for those first diagnosed over one year previously.
An article appeared in The Lancet entitled "Acquired Immunodeficiency-like Syndrome in Two Haemophiliacs" which stated that the cause of AIDs was likely a blood borne virus and that transmission of an infectious agent in blood products seemed likely. Read more about An article appeared in The Lancet entitled "Acquired Immunodeficiency-like Syndrome in Two Haemophiliacs" which stated that the cause of AIDs was likely a blood borne virus and that transmission of an infectious agent in blood products seemed likely.
The nature of the risk of AIDs was discussed by haemophilia centre directors at a meeting in January 1983. Read more about The nature of the risk of AIDs was discussed by haemophilia centre directors at a meeting in January 1983.